ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Phase II trial for F2G’s antifungal drug following EU approval
europeanpharmaceuticalreview
January 13, 2017The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to UK biotech firm F2G’s lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedospor
Pharma Sources Insight July 2025
